tiprankstipranks
Wuxi Biologics (Cayman) Inc. (MX:2269N)
:2269N
Mexico Market
2269N
Wuxi Biologics (Cayman)
RESEARCH TOOLSreports

Wuxi Biologics (Cayman) (2269N) Ratios

0 Followers

Wuxi Biologics (Cayman) Ratios

MX:2269N's free cash flow for Q2 2026 was ¥0.46. For the 2026 fiscal year, MX:2269N's free cash flow was decreased by ¥ and operating cash flow was ¥0.32. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 3.04 3.14 2.73 2.78 1.98
Quick Ratio
 2.82 2.97 2.56 2.54 1.74
Cash Ratio
 1.09 1.11 0.96 1.27 0.69
Solvency Ratio
 0.57 0.58 0.42 0.36 0.39
Operating Cash Flow Ratio
 0.56 0.77 0.61 0.61 0.59
Short-Term Operating Cash Flow Coverage
 20.39 7.31 2.14 8.10 4.19
Net Current Asset Value
¥ 14.11B¥ 15.47B¥ 12.07B¥ 8.64B¥ 5.12B
Leverage Ratios
Debt-to-Assets Ratio
 0.04 0.05 0.09 0.08 0.09
Debt-to-Equity Ratio
 0.06 0.07 0.12 0.11 0.13
Debt-to-Capital Ratio
 0.05 0.06 0.11 0.10 0.11
Long-Term Debt-to-Capital Ratio
 <0.01 <0.01 <0.01 0.04 0.04
Financial Leverage Ratio
 1.36 1.35 1.36 1.40 1.41
Debt Service Coverage Ratio
 22.53 6.32 2.14 6.67 3.91
Interest Coverage Ratio
 74.60 47.65 31.56 28.08 67.44
Debt to Market Cap
 <0.01 <0.01 0.04 0.02 0.01
Interest Debt Per Share
 0.69 0.78 1.25 1.13 1.08
Net Debt to EBITDA
 -0.70 -0.77 -0.52 -0.93 -0.32
Profitability Margins
Gross Profit Margin
47.47%45.98%40.97%40.08%44.04%
EBIT Margin
32.38%30.50%26.73%25.43%35.51%
EBITDA Margin
37.43%36.37%34.43%32.30%40.76%
Operating Profit Margin
32.36%30.47%26.63%26.12%28.44%
Pretax Profit Margin
31.10%33.30%25.89%24.50%35.09%
Net Profit Margin
21.20%22.53%17.97%19.96%28.95%
Continuous Operations Profit Margin
24.94%26.31%21.13%20.96%29.80%
Net Income Per EBT
68.17%67.64%69.42%81.45%82.50%
EBT Per EBIT
96.13%109.29%97.20%93.79%123.40%
Return on Assets (ROA)
7.66%7.70%5.89%6.01%8.92%
Return on Equity (ROE)
10.51%10.38%8.03%8.43%12.61%
Return on Capital Employed (ROCE)
13.37%11.98%10.29%9.09%10.79%
Return on Invested Capital (ROIC)
10.60%9.26%7.96%7.66%8.84%
Return on Tangible Assets
8.04%7.95%6.10%6.23%9.31%
Earnings Yield
2.93%4.16%4.99%3.14%2.00%
Efficiency Ratios
Receivables Turnover
 2.75 2.45 3.23 2.73 2.96
Payables Turnover
 9.08 10.78 14.76 12.25 10.76
Inventory Turnover
 6.81 8.17 7.25 5.78 3.75
Fixed Asset Turnover
 0.75 0.73 0.66 0.57 0.59
Asset Turnover
 0.36 0.34 0.33 0.30 0.31
Working Capital Turnover Ratio
 1.37 1.33 1.31 1.50 1.50
Cash Conversion Cycle
 146.05 159.89 138.74 167.23 186.81
Days of Sales Outstanding
 132.62 149.07 113.10 133.88 123.31
Days of Inventory Outstanding
 53.62 44.67 50.38 63.15 97.43
Days of Payables Outstanding
 40.19 33.86 24.74 29.80 33.93
Operating Cycle
 186.24 193.74 163.48 197.03 220.75
Cash Flow Ratios
Operating Cash Flow Per Share
 1.12 1.53 1.28 1.12 1.33
Free Cash Flow Per Share
 0.68 0.67 0.32 0.11 -0.08
CapEx Per Share
 0.44 0.86 0.96 1.02 1.41
Free Cash Flow to Operating Cash Flow
 0.61 0.44 0.25 0.09 -0.06
Dividend Paid and CapEx Coverage Ratio
 2.54 1.78 1.33 1.10 0.94
Capital Expenditure Coverage Ratio
 2.54 1.78 1.33 1.10 0.94
Operating Cash Flow Coverage Ratio
 1.69 2.06 1.06 1.02 1.25
Operating Cash Flow to Sales Ratio
 0.19 0.29 0.28 0.27 0.36
Free Cash Flow Yield
1.61%2.37%1.91%0.40%-0.15%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 34.86 24.34 20.06 31.85 49.89
Price-to-Sales (P/S) Ratio
 7.40 5.41 3.60 6.36 14.44
Price-to-Book (P/B) Ratio
 3.60 2.49 1.61 2.68 6.29
Price-to-Free Cash Flow (P/FCF) Ratio
 62.65 42.13 52.28 247.65 -674.95
Price-to-Operating Cash Flow Ratio
 37.58 18.46 12.90 23.20 39.79
Price-to-Earnings Growth (PEG) Ratio
 1.76 0.59 0.00 -1.41 1.62
Price-to-Fair Value
 3.60 2.49 1.61 2.68 6.29
Enterprise Value Multiple
 19.07 14.11 9.95 18.75 35.12
Enterprise Value
 166.92B 111.80B 63.98B 103.16B 218.55B
EV to EBITDA
 18.88 14.11 9.95 18.75 35.12
EV to Sales
 7.07 5.13 3.43 6.06 14.31
EV to Free Cash Flow
 59.82 39.95 49.69 235.97 -668.91
EV to Operating Cash Flow
 36.30 17.50 12.26 22.10 39.44
Tangible Book Value Per Share
 12.56 12.23 10.66 10.08 8.18
Shareholders’ Equity Per Share
 11.73 11.32 10.24 9.69 8.40
Tax and Other Ratios
Effective Tax Rate
 0.20 0.21 0.18 0.14 0.15
Revenue Per Share
 5.77 5.22 4.57 4.09 3.66
Net Income Per Share
 1.22 1.18 0.82 0.82 1.06
Tax Burden
 0.68 0.68 0.69 0.81 0.83
Interest Burden
 0.96 1.09 0.97 0.96 0.99
Research & Development to Revenue
 0.04 0.04 0.04 0.05 0.04
SG&A to Revenue
 0.11 0.11 0.11 0.09 0.08
Stock-Based Compensation to Revenue
 0.02 0.04 0.07 0.07 0.08
Income Quality
 0.93 1.30 1.08 1.37 1.25
Currency in CNY